NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 248 filers reported holding NEKTAR THERAPEUTICS in Q4 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $1,028,000 | -14.5% | 51,403 | -29.1% | 0.05% | -33.3% |
| Q3 2020 | $1,203,000 | -28.4% | 72,500 | 0.0% | 0.07% | -30.8% |
| Q2 2020 | $1,679,000 | +71.3% | 72,500 | +32.1% | 0.10% | +55.2% |
| Q1 2020 | $980,000 | +7.6% | 54,900 | +30.1% | 0.07% | +55.8% |
| Q4 2019 | $911,000 | +18.5% | 42,200 | 0.0% | 0.04% | +26.5% |
| Q3 2019 | $769,000 | -48.8% | 42,200 | 0.0% | 0.03% | -42.4% |
| Q2 2019 | $1,501,000 | +5.9% | 42,200 | 0.0% | 0.06% | -1.7% |
| Q1 2019 | $1,418,000 | +2.2% | 42,200 | -0.0% | 0.06% | -14.3% |
| Q4 2018 | $1,387,000 | -51.9% | 42,202 | -10.8% | 0.07% | -33.3% |
| Q3 2018 | $2,884,000 | +60.9% | 47,302 | +28.9% | 0.10% | +69.4% |
| Q2 2018 | $1,792,000 | +643.6% | 36,700 | +58.9% | 0.06% | +1140.0% |
| Q3 2013 | $241,000 | – | 23,100 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |